BMO Capital analyst Alex Arfaei maintained a Buy rating on AstraZeneca (NYSE: AZN) today and set a price target of $45. The company’s shares closed yesterday at $37.07.
According to TipRanks.com, Arfaei is a 4-star analyst with an average return of 7.4% and a 69.8% success rate. Arfaei covers the Healthcare sector, focusing on stocks such as Merck & Company, Eli Lilly & Co, and Bristol Myers.
AstraZeneca has an analyst consensus of Moderate Buy, with a price target consensus of $43.50.
See today’s analyst top recommended stocks >>
The company has a one-year high of $39.76 and a one-year low of $31.71. Currently, AstraZeneca has an average volume of 3.7M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
AstraZeneca Plc is a holding company, which engages in the research, development and manufacturing of pharmaceutical products. The company produces and commercializes medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology, and infectious diseases.
